# US 2016/0256409 A1 · Method for protection and improvement of liver health with meso-zeaxanthin compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256409 A1
- Document ID: US20160256409A1
- Status: Published application
- Kind: A1
- Application number: 15/058,823
- Filed: 2016-03-02
- Published: 2016-09-08
- Earliest claimed: 2015-03-02
- Assignees: OmniActive Health Technologies Limited
- Applicants: Omniactive Health Technologies Limited
- Inventors: Jayant DESHPANDE; Vijaya JUTURU; Abhijit BHATTACHARYA
- Web page: https://patentgrep.com/patent/US20160256409A1

## CPC

- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for protection, treatment and improvement of liver health includes administering a meso-zeaxanthin composition in an effective amount to a subject in need thereof. In particular, methods are described of administering a meso-zexanthin composition to a subject fed with high fat diet (HFD), and studying the effect of meso-zeaxanthin for treatment of fatty liver condition, through evaluation of various parameters such as biochemical indicators, anti-inflammatory markers, and nutritional markers.

## Claims

### Claim 1

A method for protection, improvement and treatment of liver health, comprising administering a meso-zeaxanthin composition in an effective amount to a subject fed with a high fat diet to treat fatty liver disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fatty liver disease is a non-alcoholic fatty liver disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the effective amount of meso-zeaxanthin composition administered to the subject fed with high fat diet is about 0.1 to about 200 mg/kg body weight.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition includes regulating blood glucose as a biochemical indicator of lipid metabolism.

### Claim 5 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition includes regulating insulin as a biochemical indicator of lipid metabolism.

### Claim 6 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition to a subject fed with high fat diet, includes regulating free fatty acids, as a biochemical indicator of lipid metabolism.

### Claim 7 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition to the subject fed with high fat diet includes regulating adiponectin to increased levels, as a biochemical indicator of lipid metabolism.

### Claim 8 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition to the subject fed with high fat diet, includes regulating lipid content in liver.

### Claim 9 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition to the subject fed with high fat diet includes regulating levels of cholesterol and triglycerides to decreased levels, as compared with a subject administered with high fat diet alone.

### Claim 10 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition to the subject fed with high fat diet includes regulating body weight, liver weight, visceral fat, and liver weight: body weight ratio to decreased levels, as compared with a subject administered with high fat diet alone.

### Claim 11 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition to the subject fed with high fat diet includes regulating antioxidant enzyme to an increased level, as compared with a subject administered with high fat diet alone.

### Claim 12 (depends on 11)

The method of claim 11, wherein the antioxidant enzyme includes one or more of catalase, superoxide dismutase, glutathione peroxide.

### Claim 13 (depends on 1)

The method of claim 1, wherein the step of administering the meso-zeaxanthin composition to the subject fed with high fat diet includes regulating oxidative stress through decrease in levels of malondialdehyde (MDA), as compared to a subject administered with high fat diet alone.

### Claim 14 (depends on 1)

The method of claim 1, further comprising comparing the subject fed with high fat diet administered with the meso-zeaxanthin composition to a subject administered with high fat diet alone for detection of relative liver health.